<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38317305</article-id><article-id pub-id-type="pmc">PMC467029</article-id>
<article-id pub-id-type="publisher-id">IJO-72-409</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_1636_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of tear film in patients with AIDS without opportunistic ocular infections in the era of COVID-19: A case&#x02013;control study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ruan</surname><given-names>Fang</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Qian</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref><xref rid="fn1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Wenjun</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Hongwei</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Wenbin</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn2" ref-type="author-notes">$</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jie</surname><given-names>Ying</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn2" ref-type="author-notes">$</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Ophthalmology, Beijing You&#x02019;an Hospital, Capital Medical University, Beijing Infectious Eye Disease Diagnosis and Treatment Center, Beijing, China</aff><aff id="aff2"><label>2</label>Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China</aff><aff id="aff3"><label>3</label>Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Tianjin Eye Institute, Nankai University Affiliated Eye Hospital, Tianjin, China</aff><aff id="aff4"><label>4</label>Nankai University Eye Institute, Nankai University, Tianjin, China</aff><aff id="aff5"><label>5</label>Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Prof. Ying Jie, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Lab, No. 1 Dongjiaomin Lane, Dong Cheng District, Beijing - 100730, China. E-mail: <email xlink:href="jie_yingcn@aliyun.com">jie_yingcn@aliyun.com</email></corresp><fn id="fn1"><label>#</label><p>Joint first authors.</p></fn><fn id="fn2"><label>$</label><p>Joint corresponding authors.</p></fn></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>05</day><month>2</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S409</fpage><lpage>S414</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>06</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>The assessment of tear film and ocular surface conditions in patients with acquired immunodeficiency syndrome (AIDS) has been poorly studied thus far. We aim to assess tear film parameters, ocular surface characteristics, and dry eye disease (DED) symptoms of patients with AIDS who did not undergo highly active antiretroviral treatment (HAART).</p></sec><sec id="st2"><title>Methods:</title><p>This case&#x02013;control study included 154 age-, sex-, and ethnicity-matched healthy controls and patients with AIDS. All participants underwent comprehensive ocular surface assessment and subjective DED symptomology evaluation. Data were collected between March 2022 and July 2022.</p></sec><sec id="st3"><title>Results:</title><p>HAART-na&#x000ef;ve patients with AIDS had a shorter noninvasive tear film breakup time (median 3.76 vs. 8.54 s), thinner tear film lipid layer thickness (median 73.00 vs. 91.00 nm), and lower Schirmer I test values (median 5.00 mm/5 min vs. 12.00 mm/5 min) (all <italic toggle="yes">P</italic> &#x0003c; 0.001). Moreover, higher corneal fluorescein staining scores (median 1.00 vs. 0.00) and higher upper, lower, and total meibomian gland grades were observed in AIDS patients (all <italic toggle="yes">P</italic> &#x0003c; 0.05). Negative correlations between the blood viral load and the Ocular Surface Disease Index score (<italic toggle="yes">r</italic> = -3.50, <italic toggle="yes">P</italic> = 0.027) and the Schirmer I test score (<italic toggle="yes">r</italic> = -0.374, <italic toggle="yes">P</italic> = 0.017) were detected in patients with AIDS.</p></sec><sec id="st4"><title>Conclusion:</title><p>Altered tear film status was observed in individuals with HAART-na&#x000ef;ve AIDS, even when there were no other ocular symptoms present. Therefore, patients with AIDS should be encouraged to undergo comprehensive ocular surface examinations to detect any subclinical tear film alterations occurring.</p></sec></abstract><kwd-group><kwd>AIDS</kwd><kwd>dry eye</kwd><kwd>HIV</kwd><kwd>meibomian gland</kwd><kwd>ocular surface</kwd><kwd>tear film</kwd></kwd-group></article-meta></front><body><p>Human immunodeficiency virus (HIV) attacks the immune system mainly by decreasing the number of CD4+ T lymphocytes, which ultimately leads to cellular immunodeficiency and causes tumors or opportunistic infections that is, acquired immunodeficiency syndrome (AIDS). AIDS remains a major public health issue, with the Joint United Nations Program on HIV/AIDS (UNAIDS) estimating that by the end of 2020, 37.7 million people would be living with HIV/AIDS and 1.5 million would be newly infected with HIV, but only 27.5 million would be receiving highly active antiretroviral treatment (HAART).[<xref rid="R1" ref-type="bibr">1</xref>] Although the United Nations promulgated the Political Declaration on HIV and AIDS, &#x0201c;Ending Inequalities and Getting on Track to End AIDS by 2030&#x0201d; on June 8, 2021, the coronavirus disease 2019 (COVID-19) pandemic exacerbated existing inequalities, created additional setbacks, and further derailed the AIDS response.</p><p>Since AIDS was first reported in 1981, ophthalmologists and infectious disease physicians had focused on late-stage sight-threatening complications of the posterior segment, such as cytomegalovirus retinitis (CMVR).[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref>] Recent studies have shown that that even in the absence of opportunistic ocular infections, HIV-positive individuals develop insidious and subclinical ocular changes, such as thinning of the retinal nerve fiber layer and retinal electrophysiological defects, which were thought to be associated with a low CD4 count.[<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref>] HIV-related visual disorders reflect changes ranging from infectious complications induced by immunodeficiency to ocular complications induced by immune recovery, drug treatment, or accelerated aging.</p><p>Regarding alterations in the anterior segment of the eye, dry eye disease (DED) has a prevalence rate of 5%&#x02013;50% in the general population,[<xref rid="R7" ref-type="bibr">7</xref>] and previous studies indicated that DED appeared to be more common among patients with AIDS, at around 21.4%&#x02013;23.6% in men[<xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref>] and 16.9% in women.[<xref rid="R10" ref-type="bibr">10</xref>] However, these studies were conducted without controlling for the stage of HIV infection, and the Schirmer test alone was used to diagnose DED, which is currently unstandardized based on the latest diagnostic criteria of the Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II).[<xref rid="R11" ref-type="bibr">11</xref>] Also, DED may be related to psychosocial factors including anxiety, depression, and eyestrain due to lifestyle changes in the COVID-19 era, indicating that ocular surface changes during COVID-19 should be emphasized, especially for people living with HIV/AIDS in resource-limited settings who, for various reasons, have little or no access to effective treatment options.</p><p>To this end, we sought to investigate the tear film and blinking characteristics of HAART-na&#x000ef;ve AIDS patients without ocular opportunistic infections in the context of the current understanding of DED. We also aimed to explore the relationship between each ocular indicator and the patient&#x02019;s CD4 count and blood HIV viral load, without the ocular surface side effects associated with antiviral therapy.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><sec id="sec2-1"><title>Subjects</title><p>Patients with AIDS were HAART-na&#x000ef;ve inpatients from the Infectious Disease Center of Beijing You&#x02019;an Hospital, who routinely underwent ophthalmic consultations to screen for ocular lesions during their stay and provided consent for their relevant medical records to be reviewed to determine their suitability for participation in this study from March 2022 to July 2022. Age- and sex-matched, self-reported, HIV-negative individuals were recruited as healthy controls by the Department of Ophthalmology, and they consisted of patients from health checkups, hospital staff, and patients&#x02019; families. All participants were 18&#x02013;55 years of age with no history of ocular surface or intraocular diseases, corneal contact lens wear, or ocular surgery. Furthermore, patients with AIDS diagnosed with ocular opportunistic infections, HIV-associated retinal microangiopathy, or ocular tumors were excluded. Only the data from the right eyes were included in this analysis.</p><p>A total of 154 participants were eventually enrolled in this study, with an estimated 80 patients with AIDS and 74 healthy controls, far greater than the sample size requirements for the desired study power, calculated by G*Power (version 3&#x000b7;1&#x000b7;9&#x000b7;7; Erdfelder, Faul, &#x00026; Buchner, D&#x000fc;sseldorf, Germany), with noninvasive tear film breakup time (NIBUT) as the designated outcome and a normal standard deviation (SD) of 6 s.[<xref rid="R12" ref-type="bibr">12</xref>] A minimum of 19 participants were required for each group to detect a clinically significant difference of 5 s, with 80% power (&#x003b2; = 0.2), at a two-sided statistical significance level of 5% (&#x003b1; = 0.05).</p></sec><sec id="sec2-2"><title>Measurements</title><p>All participants underwent a comprehensive ocular surface assessment performed by the same ophthalmologist (Dr. F. R. and Dr. Q. F.), following the principle of invasiveness from small to large, to minimize the impact on tear film physiology. Among the ocular indicators observed, NIBUT and meibomian gland loss (MGL) were measured using a Keratograph 5M (K5M; Oculus, Optikgerate, Germany), and tear film lipid layer thickness (LLT) and blinking pattern were calculated using a LipiView interferometer (TearScience, Morrisville, NC, USA). The temperature of the clinic was controlled between 22&#x000b0;C and 25&#x000b0;C and the relative humidity was 50%&#x02013;55%.</p></sec><sec id="sec2-3"><title>DED symptomology evaluation</title><p>DED symptoms were assessed using the Ocular Surface Disease Index (OSDI) questionnaire on a scale of 0&#x02013;100, which consisted of 12 questions. Questions 1&#x02013;5 were on symptoms of eye discomfort, questions 6&#x02013;9 were on limitations of daily activities, and questions 10&#x02013;12 were on environmental triggers, with higher scores representing greater disability.[<xref rid="R13" ref-type="bibr">13</xref>]</p></sec><sec id="sec2-4"><title>Tear film and blinking pattern evaluation</title><p>Tear film LLT was measured quantitatively using LipiView with a detection time of 20 s, during which the patient blinked normally while fixating on an internal fixation target consisting of light-emitting diodes. The outcomes were represented in interferometric color units (ICU), with one ICU representing 1 nm; there was an upper detection limit of 100 nm.[<xref rid="R14" ref-type="bibr">14</xref>] The blinking pattern was detected using LipiView simultaneously with LLT measurement, and the partial blinking rate (PBR) was expressed as the ratio of incomplete blinking to total blinking. NIBUT representative tear film stability was contactless and automatically gauged by K5M, a commercially available corneal topography instrument that used automated videokeratoscopy to record the first time and location of the subject&#x02019;s tear film breakup by monitoring the contours of the reflected 22-ring Placido disc mires distortion.[<xref rid="R15" ref-type="bibr">15</xref>] After blinking twice, the subjects were asked to maintain fixation and refrain from blinking, and the readings were displayed. Three NIBUT readings were averaged for each case.[<xref rid="R16" ref-type="bibr">16</xref>] Schirmer I test was performed using a filter paper (Jingming, Tianjin, China) placed at the notch, and the folded end was hooked over the temporal one-third of the lower lid margin. The score in this test was based on the length of wetting from the notch after 5 min. Schirmer test without anesthesia was a standardized test that provided an estimate of the stimulus reflex tear flow.</p></sec><sec id="sec2-5"><title>Ocular surface damage evaluation</title><p>Vital corneal fluorescein staining (CFS) scores were obtained using sodium fluorescein in the inferior fornix to determine the degree of corneal epitheliopathy. The score was based on the National Eye Institute/Industry grading scale, which divided the cornea into five sections; each section was graded from 0 (absent) to 3 (severe) based on the dye distribution on the background of cobalt blue light, ranging from to 0 to 15.[<xref rid="R14" ref-type="bibr">14</xref>]</p></sec><sec id="sec2-6"><title>MGL evaluation</title><p>MGL of the upper and lower eyelids was graded by infrared meibography using K5M in the Meibo-Scan enhanced contrast according to the criteria of Arita <italic toggle="yes">et al</italic>., with the eyelids turned over. The grades denoted the following: grade 0, no loss of meibomian glands; grade 1, the loss was less than one-third of the total meibomian gland area; grade 2, loss between one third and two thirds; and grade 3, loss of more than two thirds.[<xref rid="R17" ref-type="bibr">17</xref>] The upper, lower, and total MGL grades were recorded separately, ranging from 0 to 6.</p></sec><sec id="sec2-7"><title>DED diagnosis</title><p>The diagnostic criteria for DED were based on the TFOS DEWS II Diagnostic Methodology report; if the OSDI score was &#x02265;13 and NIBUT was &#x0003c;10 s or CFS showed &#x0003e;5 corneal spots, a dry eye diagnosis could be made.</p></sec><sec id="sec2-8"><title>Statistical analysis</title><p>Statistical analyses were performed using IBM Statistical Package for the Social Sciences (SPSS) Statistics software (version 26&#x000b7;0; New York, NY, USA). The measurement data were tested for normality using the Shapiro&#x02013;Wilk test, and the Mann&#x02013;Whitney U test was used for non-normally distributed data, presented as median (interquartile range [IQR]) for comparison between patients with AIDS and healthy controls. The Chi-square test was used for ordinary enumeration data, and Fisher&#x02019;s exact test was used for comparisons between groups for enumeration data of different grouping levels, all expressed as <italic toggle="yes">n</italic> (%). Spearman&#x02019;s rank correlation analysis was used for measurement data. Statistical significance was set at <italic toggle="yes">P</italic> &#x0003c; 0&#x000b7;05.</p></sec><sec id="sec2-9"><title>Ethics approval</title><p>This cross-sectional, observational, case&#x02013;control study adhered to the tenets of the Declaration of Helsinki. It was approved by the Institutional Ethics Committee of Beijing You&#x02019;an Hospital, Capital Medical University (ID: 2017011) and is registered with the Chinese Clinical Trial Registry (ID: ChiCTR2200056955). Written informed consent was obtained from all the participants before any test procedures were performed.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><p>The subjects in both groups were Chinese men. The demographic and clinical data of all participants, comprising 80 AIDS patients and 74 healthy controls, are summarized in <xref rid="IJO.IJO_1636_23-T1" ref-type="table">Table 1</xref>. Ocular clinical measurements are presented in <xref rid="IJO.IJO_1636_23-T2" ref-type="table">Table 2</xref>. Tear film tests revealed a shorter NIBUT (median 3.76 vs. 8.54 s), thinner LLT (median 73.00 vs. 91.00 nm), and lower Schirmer I test values (median 5.00 mm/5 min vs. 12.00 mm/5 min) in AIDS patients when compared to healthy controls (all <italic toggle="yes">P</italic> &#x0003c; 0.001) [<xref rid="IJO.IJO_1636_23-F1" ref-type="fig">Fig. 1</xref>]. Concerning ocular damage, patients with AIDS were more likely to show mild corneal epithelial damage as evidenced by higher CFS scores (median 1.00 vs. 0.00, <italic toggle="yes">P</italic> &#x0003c; 0.001) and more severe meibomian gland atrophy in terms of higher upper, lower, and total MGL grades (all <italic toggle="yes">P</italic> &#x0003c; 0.05) [<xref rid="IJO.IJO_1636_23-F2" ref-type="fig">Fig. 2</xref>]. However, there were no significant differences in the prevalence of DED, OSDI scores, or blinking patterns between the two groups (all <italic toggle="yes">P</italic> &#x0003e; 0.05).</p><table-wrap position="float" id="IJO.IJO_1636_23-T1"><label>Table 1</label><caption><p>Participants&#x02019; demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">AIDS patients (<italic toggle="yes">n</italic>=80)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Healthy controls (<italic toggle="yes">n</italic>=74)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">35.00 (30.00, 47.75)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33.00 (28.00, 42.50)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" rowspan="1" colspan="1">Men</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">80 (100%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">74 (100%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Asian Chinese (100%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Asian Chinese (100%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CD4 T-cell count (cells/mm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33.00 (15.50, 33.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Blood viral load (RNA copies/ml)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">31,217.50 (616.75, 162,659.25)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>AIDS=Acquired immunodeficiency syndrome, HIV=Human immunodeficiency virus. The reference value of the CD4+ T-cell count is 500&#x02013;1600 cells/mm<sup>3</sup>. Usually, the lower limit of blood HIV load detection is 40 copies/ml. If it is lower than this value, it means that the virus is not detected; if it is higher than the lower limit, it indicates that the virus has infected the patient and the patient needs to start highly active antiretroviral treatment. Data are presented as median (interquartile range) or the number of participants (% of participants)</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="IJO.IJO_1636_23-T2"><label>Table 2</label><caption><p>Tear film and ocular surface characteristics of participants with AIDS and healthy controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Grade</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">AIDS patients (<italic toggle="yes">n</italic>=80)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Healthy controls (<italic toggle="yes">n</italic>=74)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dry eye diagnosis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TFOS DEWS II criteria</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30 (37.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20 (27.0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.327</td></tr><tr><td align="left" rowspan="1" colspan="1">Dry eye symptomology</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OSDI score</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11.70 (6.25, 22.02)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12.60 (3.15, 16.45)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" rowspan="1" colspan="1">Tear film characteristics</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Noninvasive tear film breakup time (s)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3.76 (2.68, 5.88)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8.54 (7.40, 10.49)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Tear film lipid layer thickness (nm)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">73.00 (57.00, 84.25)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">91.00 (73.50, 100.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Schirmer I test (mm/5 min)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5.00 (2.00, 8.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12.00 (7.00, 16.50)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Blinking pattern characteristics</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Number of incomplete blinks (/20 s)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.00 (2.25, 6.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3.00 (1.00, 5.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of total blinks (/20 s)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.00 (4.00, 9.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.00 (3.75, 8.25)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.941</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial blinking rate</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.89 (0.58, 1.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.75 (0.18, 1.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.086</td></tr><tr><td align="left" rowspan="1" colspan="1">Damage to the ocular surface</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Corneal fluorescein staining score</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00 (0, 2.75)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0, 1.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Meibomian gland dropout</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Upper meibomian gland loss grade</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">34 (45.9%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">42 (52.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38 (51.4%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">34 (42.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lower meibomian gland loss grade</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">32 (40.0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38 (51.4%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.044*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">39 (48.8%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">36 (48.6%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9 (11.2%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total meibomian gland loss grade</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14 (18.9%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24 (30.0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">48 (64.9%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">28 (35.0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 (16.2%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">26 (32.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Grade 4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>AIDS=Acquired immunodeficiency syndrome, OSDI=Ocular Surface Disease Index, TFOS DEWS II=The Tear Film and Ocular Surface Society Dry Eye Workshop II. Data are presented as median (interquartile range) or the number of participants (% of participants). Asterisks denote statistically significant differences (<italic toggle="yes">P</italic>&#x0003c;0.05)</p></fn></table-wrap-foot></table-wrap><fig position="float" id="IJO.IJO_1636_23-F1"><label>Figure 1</label><caption><p>Tear film parameters in AIDS patients and healthy controls. AIDS = acquired immunodeficiency syndrome</p></caption><graphic xlink:href="IJO-72-409-g001" position="float"/></fig><fig position="float" id="IJO.IJO_1636_23-F2"><label>Figure 2</label><caption><p>Comparison of Meibo-Scan enhanced contrast meibography (left part of each picture) and regular infrared meibomian gland images (right part of each picture) from the superior and inferior eyelids in an HIV-negative adult (a and b) and an AIDS patient (c and d) of the same age. AIDS = acquired immunodeficiency syndrome, HIV = human immunodeficiency virus</p></caption><graphic xlink:href="IJO-72-409-g002" position="float"/></fig><p>Correlations between the CD4+ T-cell count and blood viral load in patients with AIDS and ocular findings are shown in <xref rid="IJO.IJO_1636_23-T3" ref-type="table">Table 3</xref>. Significant negative correlations between the blood viral load and OSDI score (<italic toggle="yes">r</italic> = -3.50, <italic toggle="yes">P</italic> = 0.027) and Schirmer I test (<italic toggle="yes">r</italic> = -0.374, <italic toggle="yes">P</italic> = 0.017) were detected in patients with AIDS. No significant correlation was observed between the CD4 count and ocular indicators.</p><table-wrap position="float" id="IJO.IJO_1636_23-T3"><label>Table 3</label><caption><p>Correlation analysis of CD4 T-cell counts and the blood viral load of AIDS patients with other ocular surface parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Ocular parameters</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">CD4 T-cell count<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Blood viral load<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">r</italic>
<sub>s</sub>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">r</italic>
<sub>s</sub>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dry eye diagnosis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.076</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.641</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.130</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.425</td></tr><tr><td align="left" rowspan="1" colspan="1">OSDI score</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.034</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.837</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.350</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.027*</td></tr><tr><td align="left" rowspan="1" colspan="1">Noninvasive tear film breakup time</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.084</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.608</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.031</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.849</td></tr><tr><td align="left" rowspan="1" colspan="1">Tear film lipid layer thickness</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.219</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.174</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.113</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.489</td></tr><tr><td align="left" rowspan="1" colspan="1">Schirmer I test</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.303</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.058</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.374</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.017*</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of incomplete blinks</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.218</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.176</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.061</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.708</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of total blinks</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.304</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.057</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.155</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.339</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial blinking rate</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.244</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.129</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.077</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.638</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal fluorescein staining score</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.177</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.276</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.093</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.566</td></tr><tr><td align="left" rowspan="1" colspan="1">Upper meibomian gland loss grade</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.212</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.103</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.029</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.822</td></tr><tr><td align="left" rowspan="1" colspan="1">Lower meibomian gland loss grade</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.121</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.341</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.026</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.837</td></tr><tr><td align="left" rowspan="1" colspan="1">Total meibomian gland loss grade</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.070</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.576</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-0.068</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.585</td></tr></tbody></table><table-wrap-foot><fn id="TF-F3"><p>AIDS=Acquired immunodeficiency syndrome, OSDI=Ocular Surface Disease Index. Data are presented as Spearman&#x02019;s rank correlation coefficients. Asterisks denote statistically significant value (<italic toggle="yes">P</italic>&#x0003c;0.05)</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>In this case&#x02013;control study, we conducted a novel and comprehensive evaluation of the ocular surface manifestations of patients with HAART-na&#x000ef;ve AIDS and HIV-negative individuals, particularly those with DED. The tear film status was altered in patients with AIDS, even without significant ocular symptoms. Notably, these patients were not receiving HAART therapy, so any ocular effects related to antiviral therapy were ruled out.</p><p>A stable tear film is the cornerstone of ocular surface health, forming the primary refractive surface for light entering the visual system and protecting and nourishing the corneal tissue.[<xref rid="R18" ref-type="bibr">18</xref>] Since the 2017 TFOS DEWS II highlighted the loss of tear film homeostasis as the most central pathophysiological alteration in DED,[<xref rid="R19" ref-type="bibr">19</xref>] NIBUT measured by K5M has been more widely used in clinical and scientific research as a noninvasive tool for more accurate measurement of the timing and characteristics of tear film breakup.[<xref rid="R20" ref-type="bibr">20</xref>] Importantly, we found tear film instability in patients with AIDS, as evidenced by a significant shortening of NIBUT, which has rarely been mentioned in conventional literature.</p><p>Abnormal tear production and Sj&#x000f6;gren syndrome (SS)-like illness in patients with HIV/AIDS have been reported in many studies.[<xref rid="R21" ref-type="bibr">21</xref>] Indeed, this study found a significant decrease in Schirmer I test values as an evidence of aqueous deficiency in patients with AIDS. It is well known that the bulk of the tear film volume is secreted by the lacrimal glands, and current studies suggest that HIV infection causes salivary gland and lacrimal gland dysfunction, leading to dry mouth and DED symptoms. The common underlying cause is diffuse infiltrative lymphocytosis syndrome (DILS) due to glandular infiltration with CD8+ T cells in the presence of reduced CD4+ counts.[<xref rid="R22" ref-type="bibr">22</xref>] It should be noted that sicca symptoms, such as xerostomia and xerophthalmia, might also be present.[<xref rid="R23" ref-type="bibr">23</xref>] SS patients are positive for antinuclear antibody, SS-A, SS-B, or rheumatoid factor, while DILS in HIV/AIDS patients is mostly devoid of these autoantibody abnormalities. In this study, an increased blood HIV viral load was correlated with reduced Schirmer I test measurements in AIDS patients, suggesting an effect on tear production as the infection progressed. Several studies have reported that HIV-1 viral particles could be detected in the tears of HIV/AIDS patients,[<xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref>] suggesting that tear-associated tissues could also be reservoirs for HIV, reflecting the relationship between HIV infection and lacrimal gland tissue.</p><p>The LipiView interferometer measurements also revealed mild thinning of the tear film LLT in AIDS patients. Nevertheless, the upper detection limit of the machine was only 100 nm; thus, we suspected that if the measurement range was wider, the difference in LLT between the two groups would be more pronounced. The optimal LLT lowered the preocular surface tension at the air/tear interface, spread the tear film on the ocular surface, and retarded tear evaporation. However, the tear evaporation rate was not greatly affected unless LLT was less than 24 nm or was completely absent,[<xref rid="R26" ref-type="bibr">26</xref>] and no AIDS patient had measurements below the lower limit in the present study. Although thinning of LLT in AIDS patients was not extremely severe, it could be considered part of the subclinical changes in the ocular surface in these patients, like thinning of the retinal nerve fiber layer and retinal electrophysiological defects in HIV-positive individuals.[<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref>]</p><p>Given that the tear film lipid layer is mainly composed of meibum secreted by the meibomian gland and distributed on the tear film during each blink, we further analyzed the blinking pattern and meibomian gland dropout in patients with AIDS using interferometry and meibography. We observed a greater loss of the upper, lower, and total meibomian glands in patients with AIDS compared to normal controls, which is consistent with findings from a previous study which reported that meibomian gland dropout was greater in HIV-positive individuals, even on regular HAART, and was correlated with the severity of disease at diagnosis, reflecting the significant immune impairment present in this cohort before diagnosis and treatment.[<xref rid="R27" ref-type="bibr">27</xref>] Therefore, at the end stage of HIV infection, the absence and impairment of the meibomian glands in patients with AIDS could be even more pronounced.</p><p>We accurately reported 37.5% prevalence of DED in patients with AIDS based on the TFOS DEWS II dry eye diagnostic criteria; however, we were surprised that there was no statistically significant difference in this value compared to sex-, age-, and ethnicity-matched healthy controls, unlike what had been reported in previous studies. While the reasons for this were unclear, it was conceivable that the lack of intergroup differences was relevant to the current standard of diagnosis, as the difference in subjective symptoms between the two groups was not significant, and no statistical difference was found on comparing the OSDI scores. Ultimately, there was no significant increase in the proportion of DED diagnosed, even though tear film homeostasis was more severely destabilized in AIDS patients. Interestingly, there was a negative correlation between blood HIV-1 load and OSDI scores in this study, which might be associated with corneal hypoesthesia due to neuroimmunity and neurodegeneration caused by long-term HIV infection. We recommend that attention should be paid to the separation of DED symptoms and signs during diagnosis. If a patient is asymptomatic or has mild symptoms with significant tear film dysfunction or ocular surface damage, a diagnosis of DED should also be considered.</p><p>Data in this research were collected from March 25, 2022 to July 20, 2022, when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out nationwide and intermittently surged regionally in China. During the COVID-19 pandemic, the relevant stay-at-home measures, the consequent lifestyle changes, and eye fatigue adversely affected both overall visual function and the ocular surface for the public population.[<xref rid="R28" ref-type="bibr">28</xref>] Several studies investigated the ocular surface disturbance symptoms of post-COVID-19 patients, including DED, indicating the long-term effects of this infectious disease on the ocular surface.[<xref rid="R29" ref-type="bibr">29</xref><xref rid="R30" ref-type="bibr">30</xref>] In conjunction with the above, it was necessary to focus on the assessment of tear film and ocular surface conditions in HIV/AIDS patients during the pandemic, which has been poorly studied thus far. Our study offers insight for understanding the dimensions of AIDS. Although the blinking pattern characteristics of HIV/AIDS patients were not statistically different from those of the normal population in the present study, we believed that this transient pattern deserved further assessment, and future expansion of the sample size was expected to provide new clinical findings and implications.</p><p>Several limitations also need to be mentioned, including this study&#x02019;s single-center design, small sample size, and only male features. Furthermore, the case&#x02013;control design excluded ocular signs and symptoms after HAART and those outside the hospital. Studies focusing on tear osmolarity, corneal perception, and meibum quantity, quality, and expressibility are required to refine our understanding of the ocular surface characteristics of patients with AIDS. Moreover, not all HIV-infected individuals can receive effective HAART because of socioeconomic factors or the level of educational attainment, particularly in low- and middle-income countries. Therefore, ophthalmologists should pay more attention to ocular findings in patients with severe immunosuppression. Also, the variability in noninvasive tear film parameters of the used machines and platforms should not be ignored.[<xref rid="R31" ref-type="bibr">31</xref>] This study supports conducting a comprehensive ocular surface examination of patients with HIV/AIDS to detect subclinical tear film alterations. The classification of DED in patients with AIDS might include aqueous deficiency and evaporative factors requiring comprehensive treatment to avoid a consequent impairment in quality of life.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>Even in the absence of other ocular symptoms, patients with AIDS might be predisposed to have an altered tear film status, that is, poorer tear film stability, a lower tear secretion volume, a thinner tear film lipid layer, and more severe meibomian gland dropout. As the AIDS epidemic continues to spread worldwide, especially in resource-limited settings where HAART is difficult to access, an increasing number of immunosuppressed individuals are vulnerable to ocular surface problems. Therefore, future comprehensive studies are indispensable, ideally involving collaborations between ophthalmologists and AIDS clinicians.</p><sec sec-type="funding-statement" id="sec2-10"><title>Financial support and sponsorship</title><p>This study was supported by the Key Project of Tianjin Eye Hospital (QF:YKYB2007), and the Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-016A).</p></sec><sec sec-type="COI-statement" id="sec2-11"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>World Health Organisation</collab>
</person-group><article-title>Global Health Observatory (GHO) Data</article-title><comment>Available from: <uri xlink:href="https://www.who.int/news-room/fact-sheets/detail/hiv-aids">https://www.who.int/news-room/fact-sheets/detail/hiv-aids</uri></comment></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gottlieb</surname><given-names>MS</given-names></name>
<name><surname>Schroff</surname><given-names>R</given-names></name>
<name><surname>Schanker</surname><given-names>HM</given-names></name>
<name><surname>Weisman</surname><given-names>JD</given-names></name>
<name><surname>Fan</surname><given-names>PT</given-names></name>
<name><surname>Wolf</surname><given-names>RA</given-names></name>
<etal/></person-group><article-title>Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency</article-title><source>N Engl J Med</source><year>1981</year><volume>305</volume><fpage>1425</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">6272109</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cock</surname><given-names>KMD</given-names></name>
<name><surname>Jaffe</surname><given-names>HW</given-names></name>
<name><surname>Curran</surname><given-names>JW</given-names></name></person-group><article-title>Reflections on 40 years of AIDS</article-title><source>Emerg Infect Dis</source><year>2021</year><volume>27</volume><fpage>1553</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">34013858</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peters</surname><given-names>RPH</given-names></name>
<name><surname>Kestelyn</surname><given-names>PG</given-names></name>
<name><surname>Zierhut</surname><given-names>M</given-names></name>
<name><surname>Kempen</surname><given-names>JH</given-names></name></person-group><article-title>The changing global epidemic of HIV and ocular disease</article-title><source>Ocul Immunol Inflamm</source><year>2020</year><volume>28</volume><fpage>1007</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">32396027</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brand&#x000e3;o</surname><given-names>LN</given-names></name>
<name><surname>Lira</surname><given-names>RPC</given-names></name>
<name><surname>Arantes</surname><given-names>TEFE</given-names></name>
<name><surname>Costa</surname><given-names>CCM</given-names></name>
<name><surname>Silva Neto</surname><given-names>EDD</given-names></name>
<name><surname>Ara&#x000fa;jo</surname><given-names>PSR</given-names></name>
<etal/></person-group><article-title>Comparison of retinal structure using optical coherence tomography angiography between persons with and without HIV infection</article-title><source>Ocul Immunol Inflamm</source><year>2023</year><fpage>1</fpage><lpage>6</lpage><comment>doi: 10.1080/09273948.2023.2175696</comment></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geannopoulos</surname><given-names>K</given-names></name>
<name><surname>McMahan</surname><given-names>C</given-names></name>
<name><surname>Maldonado</surname><given-names>RS</given-names></name>
<name><surname>Abbott</surname><given-names>A</given-names></name>
<name><surname>Knickelbein</surname><given-names>J</given-names></name>
<name><surname>Agron</surname><given-names>E</given-names></name>
<etal/></person-group><article-title>Retinal thinning in people with well-controlled HIV infection</article-title><source>J Acquir Immune Defic Syndr</source><year>2022</year><volume>91</volume><fpage>210</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">36094488</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stapleton</surname><given-names>F</given-names></name>
<name><surname>Alves</surname><given-names>M</given-names></name>
<name><surname>Bunya</surname><given-names>VY</given-names></name>
<name><surname>Jalbert</surname><given-names>I</given-names></name>
<name><surname>Lekhanont</surname><given-names>K</given-names></name>
<name><surname>Malet</surname><given-names>F</given-names></name>
<etal/></person-group><article-title>TFOS DEWS II epidemiology report</article-title><source>Ocul Surf</source><year>2017</year><volume>15</volume><fpage>334</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">28736337</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geier</surname><given-names>SA</given-names></name>
<name><surname>Libera</surname><given-names>S</given-names></name>
<name><surname>Klauss</surname><given-names>V</given-names></name>
<name><surname>Goebel</surname><given-names>FD</given-names></name></person-group><article-title>Sicca syndrome in patients infected with the human immunodeficiency virus</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>1319</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">9097769</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lucca</surname><given-names>JA</given-names></name>
<name><surname>Farris</surname><given-names>RL</given-names></name>
<name><surname>Bielory</surname><given-names>L</given-names></name>
<name><surname>Caputo</surname><given-names>AR</given-names></name></person-group><article-title>Keratoconjunctivitis sicca in male patients infected with human immunodeficiency virus type 1</article-title><source>Ophthalmology</source><year>1990</year><volume>97</volume><fpage>1008</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">2402409</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lucca</surname><given-names>JA</given-names></name>
<name><surname>Kung</surname><given-names>JS</given-names></name>
<name><surname>Farris</surname><given-names>RL</given-names></name></person-group><article-title>Keratoconjunctivitis sicca in female patients infected with human immunodeficiency virus</article-title><source>CLAO J</source><year>1994</year><volume>20</volume><fpage>49</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">8149575</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolffsohn</surname><given-names>JS</given-names></name>
<name><surname>Arita</surname><given-names>R</given-names></name>
<name><surname>Chalmers</surname><given-names>R</given-names></name>
<name><surname>Djalilian</surname><given-names>A</given-names></name>
<name><surname>Dogru</surname><given-names>M</given-names></name>
<name><surname>Dumbleton</surname><given-names>K</given-names></name>
<etal/></person-group><article-title>TFOS DEWS II diagnostic methodology report</article-title><source>Ocul Surf</source><year>2017</year><volume>15</volume><fpage>539</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">28736342</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>ABC</given-names></name>
<name><surname>Wang</surname><given-names>MTM</given-names></name>
<name><surname>Liu</surname><given-names>K</given-names></name>
<name><surname>Prime</surname><given-names>ZJ</given-names></name>
<name><surname>Danesh-Meyer</surname><given-names>HV</given-names></name>
<name><surname>Craig</surname><given-names>JP</given-names></name></person-group><article-title>Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye</article-title><source>Ocul Surf</source><year>2018</year><volume>16</volume><fpage>289</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">29510226</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>RM</given-names></name>
<name><surname>Christianson</surname><given-names>MD</given-names></name>
<name><surname>Jacobsen</surname><given-names>G</given-names></name>
<name><surname>Hirsch</surname><given-names>JD</given-names></name>
<name><surname>Reis</surname><given-names>BL</given-names></name></person-group><article-title>Reliability and validity of the Ocular Surface Disease Index</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><fpage>615</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10815152</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jie</surname><given-names>Y</given-names></name>
<name><surname>Sella</surname><given-names>R</given-names></name>
<name><surname>Feng</surname><given-names>J</given-names></name>
<name><surname>Gomez</surname><given-names>ML</given-names></name>
<name><surname>Afshari</surname><given-names>NA</given-names></name></person-group><article-title>Evaluation of incomplete blinking as a measurement of dry eye disease</article-title><source>Ocul Surf</source><year>2019</year><volume>17</volume><fpage>440</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">31152804</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>MTM</given-names></name>
<name><surname>Craig</surname><given-names>JP</given-names></name></person-group><article-title>Evaluating the diagnostic ability of two automated non-invasive tear film stability measurement techniques</article-title><source>Cont Lens Anterior Eye</source><year>2021</year><volume>44</volume><fpage>101362</fpage><comment>doi: 10.1016/j.clae.2020.08.006</comment><pub-id pub-id-type="pmid">32919934</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Wang</surname><given-names>MTM</given-names></name>
<name><surname>Craig</surname><given-names>JP</given-names></name></person-group><article-title>Exploring the Asian ethnic predisposition to dry eye disease in a pediatric population</article-title><source>Ocul Surf</source><year>2019</year><volume>17</volume><fpage>70</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30219270</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arita</surname><given-names>R</given-names></name>
<name><surname>Itoh</surname><given-names>K</given-names></name>
<name><surname>Inoue</surname><given-names>K</given-names></name>
<name><surname>Amano</surname><given-names>S</given-names></name></person-group><article-title>Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population</article-title><source>Ophthalmology</source><year>2008</year><volume>115</volume><fpage>911</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18452765</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willcox</surname><given-names>MDP</given-names></name>
<name><surname>Arg&#x000fc;eso</surname><given-names>P</given-names></name>
<name><surname>Georgiev</surname><given-names>GA</given-names></name>
<name><surname>Holopainen</surname><given-names>JM</given-names></name>
<name><surname>Laurie</surname><given-names>GW</given-names></name>
<name><surname>Millar</surname><given-names>TJ</given-names></name>
<etal/></person-group><article-title>TFOS DEWS II tear film report</article-title><source>Ocul Surf</source><year>2017</year><volume>15</volume><fpage>366</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">28736338</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Craig</surname><given-names>JP</given-names></name>
<name><surname>Nichols</surname><given-names>KK</given-names></name>
<name><surname>Akpek</surname><given-names>EK</given-names></name>
<name><surname>Caffery</surname><given-names>B</given-names></name>
<name><surname>Dua</surname><given-names>HS</given-names></name>
<name><surname>Joo</surname><given-names>CK</given-names></name>
<etal/></person-group><article-title>TFOS DEWS II definition and classification report</article-title><source>Ocul Surf</source><year>2017</year><volume>15</volume><fpage>276</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">28736335</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>J</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<name><surname>Wei</surname><given-names>A</given-names></name>
<name><surname>Cui</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Qian</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>Assessment of tear film stability in dry eye with a newly developed keratograph</article-title><source>Cornea</source><year>2013</year><volume>32</volume><fpage>716</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">23132457</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>M</given-names></name>
<name><surname>Nakao</surname><given-names>R</given-names></name>
<name><surname>Higuchi</surname><given-names>Y</given-names></name>
<name><surname>Miyamura</surname><given-names>T</given-names></name>
<name><surname>Suematsu</surname><given-names>E</given-names></name></person-group><article-title>Sicca syndrome in patients infected with human immunodeficiency virus-1</article-title><source>Modern Rheumatol</source><year>2002</year><volume>12</volume><fpage>333</fpage><lpage>7</lpage></element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M</given-names></name>
<name><surname>Yen</surname><given-names>Y-F</given-names></name>
<name><surname>Lan</surname><given-names>Y-C</given-names></name>
<name><surname>Jen</surname><given-names>IA</given-names></name>
<name><surname>Chuang</surname><given-names>PH</given-names></name>
<name><surname>Lee</surname><given-names>CY</given-names></name>
<etal/></person-group><article-title>Risk of diffuse infiltrative lymphocytosis syndrome in HIV-infected patients: A nationwide population-based cohort study</article-title><source>J Acquir Immune Defic Syndr</source><year>2018</year><volume>79</volume><fpage>158</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">29995702</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nizamuddin</surname><given-names>I</given-names></name>
<name><surname>Koulen</surname><given-names>P</given-names></name>
<name><surname>McArthur</surname><given-names>CP</given-names></name></person-group><article-title>Contribution of HIV infection, AIDS, and antiretroviral therapy to exocrine pathogenesis in salivary and lacrimal glands</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><fpage>2747</fpage><pub-id pub-id-type="pmid">30217034</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>N</given-names></name>
<name><surname>Zhu</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Zuo</surname><given-names>L</given-names></name>
<name><surname>Ye</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Detection of HIV-1 viruses in tears of patients even under long-term HAART</article-title><source>AIDS (London, England)</source><year>2011</year><volume>25</volume><fpage>1925</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21811142</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>Z</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Du</surname><given-names>K</given-names></name>
<name><surname>Wei</surname><given-names>W</given-names></name></person-group><article-title>Detection of HIV-1 viral load in tears of HIV/AIDS patients</article-title><source>Infection</source><year>2020</year><volume>48</volume><fpage>929</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">32845429</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King-Smith</surname><given-names>PE</given-names></name>
<name><surname>Hinel</surname><given-names>EA</given-names></name>
<name><surname>Nichols</surname><given-names>JJ</given-names></name></person-group><article-title>Application of a novel interferometric method to investigate the relation between lipid layer thickness and tear film thinning</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><fpage>2418</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">20019370</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>BN</given-names></name>
<name><surname>Chung</surname><given-names>AW</given-names></name>
<name><surname>Lopez</surname><given-names>E</given-names></name>
<name><surname>Silvers</surname><given-names>J</given-names></name>
<name><surname>Kent</surname><given-names>HE</given-names></name>
<name><surname>Kent</surname><given-names>SJ</given-names></name>
<etal/></person-group><article-title>Meibomian gland dropout is associated with immunodeficiency at HIV diagnosis: Implications for dry eye disease</article-title><source>Ocul Surf</source><year>2020</year><volume>18</volume><fpage>206</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">32081622</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saldanha</surname><given-names>IJ</given-names></name>
<name><surname>Petris</surname><given-names>R</given-names></name>
<name><surname>Makara</surname><given-names>M</given-names></name>
<name><surname>Channa</surname><given-names>P</given-names></name>
<name><surname>Akpek</surname><given-names>EK</given-names></name></person-group><article-title>Impact of the COVID-19 pandemic on eye strain and dry eye symptoms</article-title><source>Ocul Surf</source><year>2021</year><volume>22</volume><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">34133976</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>KH</given-names></name>
<name><surname>Lui</surname><given-names>GCY</given-names></name>
<name><surname>Poon</surname><given-names>KCF</given-names></name>
<name><surname>Ng</surname><given-names>SSS</given-names></name>
<name><surname>Young</surname><given-names>AL</given-names></name>
<name><surname>Hui</surname><given-names>DSC</given-names></name>
<etal/></person-group><article-title>Ocular surface disturbance in patients after acute COVID-19</article-title><source>Clin Exp Ophthalmol</source><year>2022</year><volume>50</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">35218134</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stapleton</surname><given-names>F</given-names></name>
<name><surname>Abad</surname><given-names>JC</given-names></name>
<name><surname>Barabino</surname><given-names>S</given-names></name>
<name><surname>Burnett</surname><given-names>A</given-names></name>
<name><surname>Iyer</surname><given-names>G</given-names></name>
<name><surname>Lekhanont</surname><given-names>K</given-names></name>
<etal/></person-group><article-title>TFOS lifestyle: Impact of societal challenges on the ocular surface</article-title><source>Ocul Surf</source><year>2023</year><volume>28</volume><fpage>165</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">37062429</pub-id>
</element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Srivastav</surname><given-names>S</given-names></name>
<name><surname>Modiwala</surname><given-names>Z</given-names></name>
<name><surname>Ali</surname><given-names>MH</given-names></name>
<name><surname>Basu</surname><given-names>S</given-names></name></person-group><article-title>Repeatability, reproducibility and agreement between three different diagnostic imaging platforms for tear film evaluation of normal and dry eye disease</article-title><source>Eye (London, England)</source><year>2023</year><volume>37</volume><fpage>2042</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">36261494</pub-id>
</element-citation></ref></ref-list></back></article>